The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. G1 Therapeutics Inc. shares valued at $3,942 were sold by Malik Rajesh on Jan 05. At $5.41 per share, Malik Rajesh sold 729 shares. The insider’s holdings dropped to 102,739 shares worth approximately $0.38 million following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Also, Hanson James S. sold 729 shares, netting a total of over 3,942 in proceeds. Following the sale of shares at $5.41 each, the insider now holds 41,087 shares.
Before that, Moses Jennifer K. had sold 729 shares from its account. In a trade valued at $3,942, the CFO traded G1 Therapeutics Inc. shares for $5.41 each. Upon closing the transaction, the insider’s holdings decreased to 729 shares, worth approximately $0.21 million.
As published in a research note from JP Morgan on January 30, 2023, G1 Therapeutics Inc. [GTHX] has been rated up from an Underweight to a Neutral and the price target has been revised to $10 from $7. This represents a 63.3% premium over Wednesday’s closing price. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in early January. As of November 04, 2021, JP Morgan has decreased its “Neutral” rating to a “an Underweight” for GTHX.
Analyzing GTHX Stock Performance
On Wednesday, G1 Therapeutics Inc. [NASDAQ: GTHX] rose 1.38% to $3.67. The stock’s lowest price that day was $3.581, but it reached a high of $3.98 in the same session. During the last five days, there has been a drop of approximately -2.65%. Over the course of the year, G1 Therapeutics Inc. shares have dropped approximately -32.41%. Shares of the company reached a 52-week high of $8.40 on 02/02/23 and a 52-week low of $3.20 on 02/13/23. A 50-day SMA is recorded $5.73, while a 200-day SMA reached $8.23. Nevertheless, trading volume fell to 2.09 million shares from 0.71 million shares the previous day.
Support And Resistance Levels for G1 Therapeutics Inc. (GTHX)
According to the 24-hour chart, there is a support level at 3.51, which, if violated, would cause prices to drop to 3.34. In the upper region, resistance lies at 3.91. The next price resistance is at 4.14. RSI (Relative Strength Index) is 33.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.56, which suggests the price will decrease in the coming days. Percent R is at 89.78%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is G1 Therapeutics Inc. subject to short interest?
Stocks of G1 Therapeutics Inc. saw a sharp rise in short interest on Jan 30, 2023 jumping by 0.55 million shares to 3.12 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 2.57 million shares. A jump of 17.63% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.07 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.07.
Which companies own the most shares of G1 Therapeutics Inc. (GTHX)?
According to Fisher Asset Management LLC filings, the company currently owns 2,809,444 shares, which is about 5.55% of the total GTHX shares outstanding. The investor’s shares have plunged by -125,888 from its previous 13-F filing of 2935332.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $15,010,707. JPMorgan Investment Management, I acquire a 0.39% interest valued at $13.97 million while Millennium Management LLC purchased a 499,363 stake. A total of 142,334 shares of G1 Therapeutics Inc. were bought by BlackRock Fund Advisors during the quarter, and 752,067 were bought by Woodline Partners LP. In its current portfolio, Marshall Wace LLP holds 994,988 shares valued at $7.94 million.
In terms of G1 Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $11.50 in the next 12 months, up nearly 190.06% from the previous closing price of $3.62. Analysts anticipate G1 Therapeutics Inc. stock to reach $19.00 by 2023, with the lowest price target being $5.00. In spite of this, 8 analysts ranked G1 Therapeutics Inc. stock as a Buy at the end of 2023. On September 30, 2021, JP Morgan assigned a price target of “a Neutral” to the stock and downgraded coverage with a $20.